Amryt Pharma signs fifth distribution agreement in three months

Biopharmaceutical company Amryt Pharma announced further expansion in the Middle East on Tuesday, with a new distribution agreement.

Phareon Healthcare will handle distribution in Lebanon, Syria and Jordan of Amryt’s Lojuxta product, which is a therapy used for the treatment of adult patients with homozygous familial hypercholesterolaemia (HoFH).

Joe Wiley, chief executive of Amryt Pharma, said: “Pharaon Healthcare has an excellent footprint and many decades of experience in these markets, and this new agreement should help to ensure we can respond effectively to physicians' requests regarding their patients suffering with HoFH.”

HoFH is a rare, life threatening genetic cholesterol disorder which Amryt estimates will affect approximately 40 patients in the countries covered by the agreement.

“This is Amryt's fifth new distribution agreement for Lojuxta in approximately three months, and we are delighted to be partnering with Pharaon Healthcare in Lebanon, Jordan and Syria,” said Wiley.

AIM-traded Amryt holds an exclusive licence to sell Lojuxta across the European Economic Area, Middle East and North Africa, Turkey and Israel through distribution agreements with GryNumber Health, Romastru Trading, RCC Pharma and Faisal Musaed El Seif Saudi Pharmaceutical Company.

As of 0817 GMT, Amryt Pharma’s shares were up 3.11% at 19.08p.